Death domain

Source: Wikipedia, the free encyclopedia.
Death domain
SCOP2
1ddf / SCOPe / SUPFAM
CDDcd01670
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1a1w​, 1a1z​, 1d2z​, 1ddf​, 1e3y​, 1e41​, 1fad​, 1ich​, 1ik7​, 1ngr​, 1wh4​, 1wmg​, 1ygo​, 2gf5

The death domain (DD) is a

TIR domains, and ZU5 domains.[4]

Some DD-containing proteins are involved in the regulation of

innate immunity, communicating with Toll-like receptors through bipartite adapter proteins such as MyD88.[7]

The DD superfamily is one of the largest and most studied domain superfamilies. It currently comprises four subfamilies, the death domain (DD) subfamily, the death effector domain (DED) subfamily, the caspase recruitment domain (CARD) subfamily and the

Based on a genome analysis, there are 32 DDs, 7 DEDs, 28 CARDs and 19 PYDs in the human genome.[9]

Due to the large size of the death domain family protein superfamily, some death domain proteins may have a role to play in cancer and many other infections through several families of DD-proteins and specific gene alterations that have a downstream function to induce cell apoptosis. Many of these alterations occur in genes encoding mediators of apoptosis or

head and neck squamous cell carcinomas. Head and neck squamous cell carcinomas are among the cancers with the highest frequency of deregulation in genes encoding for cell death pathway constituents, with nearly half of all cases exhibiting such genomic alterations.[10]

In addition to cancer, deregulation of death receptor protein signaling and death domain recruitment is seen to influence many other human diseases. Notably, the

death inducing signaling complex
(DISC).

Specifically, in ALPS, cell apoptosis that occurs via the CD95 pathway is found to be vital in controlling the proliferation of activated lymphocytes and regulating lymphocyte homeostasis. Notably, a two-point mutation that occurs at the A1009G and E256G sites can cause a defect in apoptotic pathways in people who have ALPS (Peters, 1999). Most patients with ALPS have mutations in the Fas gene and more than 70 mutations have been mapped to its intracellular DD.[9]

See also

References

This article incorporates text from the public domain Pfam and InterPro: IPR000488